Compound Synthesis
General Clarithromycin 1 was purchased from Greenfield Chemical. Carbamoylimidazolide ketolide 5 was synthesized according to literature protocol. 27, 30 All other reagents were purchased from Sigma-Aldrich and used without further purification. Analtech silica gel plates (60 F 254 ) and Analtech preparative TLC plates (UV 254, 2000 µm) were used for analytical TLC and prep TLC purification respectively. UV light was used to examine the spots. 200-400 Mesh silica was used in column chromatography. NMR spectra were recorded on a Varian-Gemini 400 magnetic resonance spectrometer. 1 H NMR spectra are recorded in parts per million (ppm) relative to the peak of CDCl 3 , (7.24 ppm), CD 3 OD (3.31 ppm), or DMSO-d 6 (2.49 ppm). 13 C spectra were recorded relative to the central peak of the CDCl 3 triplet (77.0 ppm), CD 3 OD (49.0 ppm), or the DMSO-d 6 septet (39.7 ppm), and were recorded with complete hetero-decoupling. Multiplicities are described using the abbreviation s, singlet; d, doublet, t, triplet; q, quartet; m, multiplet; and app, apparent. Mass spectra were recorded at the Georgia Institute of Technology mass spectrometry facility in Atlanta.
C3 Azido-Ketolide (7a)
To a solution of 5 (1.55 g, 2.2 mmol), dissolved in ACN/H 2 O (5 mL: 0.5 mL), was added 6a (0.85 g, 8.5 mmol) and the mixture was allowed to stir at 55 o C for 12 h. After cooling to room temperature, the mixture was poured into DCM containing 0.5M NaH 2 PO 4 (300 mL: 200 mL). The aqueous layer was extracted with DCM (1 x 300 mL). The combined organic layers were washed with brine (300 mL) followed by drying over Na 2 SO 4 . Solvent was evaporated to yield yellow oil which was dissolved in MeOH (25 mL) and stirred at room temperature for 30 h. Solvent was evaporated and the off-white solid was purified by column chromatography (silica, EtOAc/hexanes/triethyl amine 18:1:0.1) to furnish 7a as a white foam (1.39 g, 90%).
1 H NMR (CDCl 3 , 400 MHz) 4. 1H), 4.17 (dd, J = 20.5, 8.0 Hz, 2H), 3.79 (q, J = 6.7 Hz, 1H), 2H), 3.48 (s, 1H), 1H), 2H), 3H) , 2.57 (s, 2H), 2.56 (m, 2H), 2.47 -2.38 (m, 2H), 2.31 (m, 1H), 2.21 (s, 6H), 1.86 -1.74 (m, 3H), 1.65 -1.59 (m, 2H), 1.54 -1.48 (m, 2H), 1.40 (s, 3H), 1.26 -1.15 (m, 15H), 0.92 (d, J = 6.9 Hz, 3H), 0.77 (t, J = 7.3 Hz, 3H).
13 C NMR (CDCl 3 , 101 MHz) δ 215.8, 203.3, 170.2, 169.4, 156.8, 103.6, 82.0, 79.2, 70.0, 69.2, 65.5, 60.2, 53.3, 49.4, 49.0, 47.3, 44.6, 41.0, 40.0, 39.9, 39.1, 38.6, 36.6, 28.5, 28.0, 26.5, 22.8, 21.9, 20.9, 19.9, 18.0, 14.1, 13.5, 10 
C4 Azido-Ketolide (7b)
The reaction of 5 (1.53 g, 2.17 mmol) with 6b (0.88 g, 7.7 mmol) as described for the synthesis of 7a, followed by column chromatography (silica, EtOAc/MeOH 10:1  6:1 gradient), gave 7b as white solid (0.563 g, 58% yield 203.7, 169.5, 157.1, 103.9, 82.1, 79.5, 70.2, 69.5, 65.7, 60.3, 51.1, 51.0, 50.9, 50.7, 50.5, 47.6, 44.8, 42.8, 40.2, 39.4, 38.9, 28.1, 26.2, 26.1, 24.2, 22.2, 21.1, 19.7, 18.3, 15.8, 14.6, 14.3, 13.8, 10.3 
Peptolide (12a)
A solution of DMSO (2 mL) and DIPEA (0.05 mL) was deoxygenated by bubbling Argon through for 5 min. To this, protected NLS peptide 8 (150.0 mg, 0.08 mmol) and 7a (160.9 mg, 0.23 mmol) were added, followed by CuI (13.6 mg, 0.07 mmol). The reaction was stirred at room temperature for 3 h with constant Argon blowing across the surface. The reaction was quenched by addition of NH 4 OH/NH 4 Cl (1:4, 20 mL) and extracted with 20% isopropyl alcohol (IPA) in DCM (3 x 20 mL). The combined organic layers were washed once more with NH 4 OH/NH 4 Cl (1:4, 40 mL) and concentrated in vacuo to afford a crude white solid. This crude product was purified over preparative TLC (DCM/MeOH/IPA/NH 4 OH 9:1:0.1:0.1) affording a white solid (72.2 mg). The white solid obtained above was dissolved in TFA/TIPS/phenol (90:5:5, 2 mL) and stirred at room temperature for 2 h. The reaction was quenched by addition of diethyl ether (8 mL) leading to a white precipitate. The solution was vortexed for 1 min before pelleting through centrifugation (5,000 rpm, 5 min) followed by removal of the supernatant. The pellet was washed with ether (8 mL) twice more. The final pellet was dissolved in deionized water (4 mL), ether (4 mL) was added, and the mixture was shaken. After removing the ether layer, this washing was repeated twice more. The final aqueous layer was flash frozen in dry ice/acetone and lyophilized overnight to give 12a as fluffy, white solid (59.5 mg, 39%). 
Peptolide (12b)
The reaction of protected NLS peptide 8 (154.1 mg, 0.08 mmol), 7b (167.9 mg, 0.24 mmol) and CuI (14.1 mg, 0.0740 mmol) in DMSO (2 mL) and DIPEA (0.05 mL) afforded protected analog of 12b as white solid (56.0 mg) after purification over preparative TLC (DCM/MeOH/IPA/NH 4 OH 6:0.5:0.5:0.1). Subsequent functional group deprotection in TFA/TIPS/Phenol (90:5:5, 2 mL) and product isolation as described for 12a gave 12b as fluffy, white solid (45.9 mg, 30% 
Peptolide (12c)
The reaction of protected reversed-NLS peptide 9 (18.5 mg, 9.66 µmol), 7a (21.0 mg, 30.2 µmol) and CuI (16.1 mg, 0.08 mmol) in DMSO (1 mL) and DIPEA (0.05 mL) afforded protected analog of 12c as white solid (15.9 mg) after purification over preparative TLC (DCM/MeOH/NH 4 OH 6:1:0.1). Subsequent functional group deprotection in TFA/TIPS/Phenol (90:5:5, 0.5 mL) and product isolation as described for 12a gave 12c as fluffy, white solid (7.6 mg, 40% 
Peptolide (12d)
The reaction of protected reversed-NLS peptide 9 (21.8 mg, 0.01 mmol), 7b (24.2 mg, 0.03 mmol), and CuI (13.7 mg, 0.07 mmol) in DMSO (0.5 mL), THF (0.5 mL) and DIPEA (0.1 mL, 0.57 mmol) at 55 o C for 4 h afforded protected analog of 12d as white solid (15.5 mg) after purification over preparative TLC (EtOAc/MeOH/NH 4 OH 2.5:1:0.1). Subsequent functional group deprotection in TFA/TIPS/Phenol (90:5:5, 0.5 mL) for 2.5 h and product isolation as described for 12a gave 12d as fluffy, white solid (9.4 mg, 48%). 
Peptolide (12e)
The reaction of protected plicatamide peptide 10 (23.7 mg, 0.01 mmol), 7a (23.2 mg, 0.03 mmol) and CuI (13.7 mg, 0.07 mmol) in DMSO (1 mL) and DIPEA (0.05 mL, 0.29 mmol) afforded protected analog of 12e as white solid (18.4 mg) after purification over preparative TLC (DCM/MeOH/NH 4 OH 8:1:0.1). Subsequent functional group deprotection in TFA/TIPS/Phenol (90:5:5, 0.5 mL) and product isolation as described for 12a gave 12e as fluffy, white solid (9.7 mg, 44% 
Peptolide (12f)
The reaction of protected plicatamide peptide 10 (15.8 mg, 0.0072 mmol), 7b (24.5 mg, 0.03 mmol) and CuI (14.1 mg, 0.07 mmol) in DMSO (0.5 mL), THF (0.5 mL) and DIPEA (0.1 mL, 0.57 mmol) afforded protected analog of 12f as white solid (12.5 mg) after purification over preparative TLC (DCM/MeOH/NH 4 OH 10:1:0.1). Subsequent functional group deprotection in TFA/TIPS/Phenol (90:5:5, 0.5 mL) and product isolation as described for 12a gave 12f as fluffy, white solid (6.1 mg, 42%). 
Peptolide (12g)
A reaction mixture containing protected RGD peptide 11 (151.2 mg, 0.0529 mmol), 7a (74.4 mg, 0.11 mmol) and CuI (101.3 mg, 0.53 mmol) in DMSO (0.8 mL), THF (0.8 mL) and DIPEA (0.36 mL) was stirred at rt for 18 h. To the reaction was added 20% IPA in DCM (50 mL) and the mixture washed with NH 4 OH/NH 4 Cl (1:4, 3 x 30 mL) followed by brine (30 mL). The organic layer was dried over MgSO 4 , and concentrated in vacuo to afford a crude white solid which was purified over preparative TLC (DCM/MeOH/NH 4 OH 8:1:0.1) to afford protected analog of 12g as white solid (86.4 mg). Subsequent functional group deprotection in TFA/TIPS/Phenol (90:5:5, 2 mL) and product isolation as described for 12a gave 12g as fluffy, white solid (60.6 mg, 50%). 4.02 (s, 3H), 3.92 (m, 1H), 3.85 (s, 1H), 3.77 (m, 4H), 3.54 (m, 4H), 3.50 -3.40 (m, 5H), 3.27 (m, 4H), 3.24 -3.12 (m, 10H) 
Peptolide (12h)
A reaction mixture containing protected RGD peptide 11 (99.7 mg, 0.03 mmol), 7b (55.2 mg, 0.08 mmol) and CuI (67.3 mg, 0.35 mmol) in DMSO (0.75 mL), THF (0.75 mL) and DIPEA (0.24 mL) was stirred at rt for 18 h. To the reaction was added EtOAc (30 mL) and the mixture washed with NH 4 OH/NH 4 Cl (1:4, 3 x 30 mL) followed by brine (30 mL). The organic layer was dried over MgSO 4 , and concentrated in vacuo to afford a crude white solid which was purified over preparative TLC (DCM/MeOH/NH 4 OH 10:1:0.1) to afford protected analog of 12h as white solid (35.5 mg). Subsequent functional group deprotection in TFA/TIPS/Phenol (90:5:5, 2 mL) and product isolation as described for 12a gave 12h as fluffy, white solid (18.7 mg, 27%)). 
